LLY Stock Recent News
LLY LATEST HEADLINES
The U.S. equity market has had a solid run in the past two years, buoyed by a steadily improving macroeconomic environment and strong uptake of artificial intelligence technologies. The benchmark S&P 500 index climbed almost 53% in the past two years.
It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug market is expected to generate $12.8 billion in sales this year, and according to a new report from Research and Markets, sales could swell to $104.9 billion by 2035.
The Eli Lilly and Company investment thesis highlights a robust 2024 performance, driven by a strong pipeline and solid balance sheet, supporting a positive future outlook. The company's strong cash flow and financial health underpin its ability to capitalize on growth opportunities and weather potential risks. Future outlook remains optimistic, with strategic initiatives expected to drive sustained growth and shareholder value.
Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 billion in global sales since its initial U.S. launch in 2022.
Eli Lilly (LLY 1.80%) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable healthcare company in the world, with a market cap of $730 billion.
Eli Lilly has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from country's drug regulator, it said on Thursday.
My DCF analysis suggests that Eli Lilly's stock is 60% undervalued. Defensive healthcare stocks like Eli Lilly are favorable in the current uncertain macroenvironment, driven by tariff concerns and stable Fed policies. The company's robust revenue growth, high R&D spending, and strategic positioning in the GLP-1 industry underscore its long-term growth prospects.
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Novo Nordisk (NVO) and Eli Lilly (LLY). But which of these two stocks is more attractive to value investors?
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Are you reluctant to invest in stocks right now? That's understandable.